Competing interests
HTG, A.H., Genotwin, T.J.
ONCOLOGY, EMD
M.D.G. has received research funding from Bristol Myers Squibb, Novartis, Dendreon, AstraZeneca, Merck and Genentech. He has served as a consultant to Bristol Myers Squibb, Merck, Genentech, AstraZeneca, Pfizer, EMD Serono, SeaGen, Janssen, Numab, Dragonfly, GlaxoSmithKline, Basilea, UroGen, Rappta Therapeutics, Alligator, Silverback, Fujifilm, Curis, Gilead, Bicycle, Asieris, Abbvie and Analog Devices. S.D. has served as a consultant to Janssen, Ferring, Photocure, Taris, Pacific Edge, QED, Abbvie, Janssen, Bristol Myers Squibb, Sesen, Protara, Pfizer and CG Oncology. T.B.D. has served as a consultant to Astellas, AstraZeneca, Bayer, Janssen and Sanofi. R.M. has served as a consultant to Bristol Myers Squibb, Roche, Astellas and Seattle Genetics and has received research funding from Merck and Astellas. C.K. has served as a consultant to Exelixis, Sanofi, AVEO, EMD Serono and Janssen and has received research funding from Sanofi, Gilead Sciences, AstraZeneca, ESSA Pharma, Pionyr and Incyte. He owns stock in Biogen and Epic Systems. T.J. is an employee of Genentech. A.H. has served as a consultant to HTG Molecular Diagnostics and Immunorizon. L.W. is an employee of GeneDx. K.W.M. has served as a consultant to EMD Serono, Pfizer, UroGen and Riva Therapeutics, has received research support from Pfizer and Novo Ventures, has equity in Riva Therapeutics, has received writing fees from UpToDate and has received speaking fees from OncLive. He is named on an institutional patent filed on mutational signatures of DNA repair deficiency. N.B. has served as a consultant to Apricity, BreakBio, Carisma Therapeutics, CureVac, Genetech, Novartis, Primevax, Tempest Therapeutics, Dragonfly Therapeutics, BioNTech, Genotwin and Rome Therapeutics. She has received research support from Harbour Biomed Sciences and Regeneron. J.Z. is an employee of GeneDx. S.G. received research funding from Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Genentech, Regeneron and Takeda. J.S. has served as a consultant or advisor for Natera, Pacific Edge, Merck, Urogen and Janssen. S.K.P. has received travel support form CRISPR Therapeutics and Ipsen. All remaining authors declare no competing interests.